Exelixis, Inc. $EXEL Position Lowered by Hussman Strategic Advisors Inc.

Hussman Strategic Advisors Inc. cut its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 20.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 84,000 shares of the biotechnology company’s stock after selling 21,000 shares during the period. Exelixis makes up 0.9% of Hussman Strategic Advisors Inc.’s portfolio, making the stock its 9th biggest position. Hussman Strategic Advisors Inc.’s holdings in Exelixis were worth $3,682,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of EXEL. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Exelixis by 81.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,181 shares of the biotechnology company’s stock valued at $1,592,000 after buying an additional 19,407 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Exelixis by 4.9% during the first quarter. Goldman Sachs Group Inc. now owns 1,466,779 shares of the biotechnology company’s stock valued at $54,153,000 after buying an additional 68,133 shares during the last quarter. Focus Partners Wealth boosted its position in shares of Exelixis by 83.4% during the first quarter. Focus Partners Wealth now owns 38,458 shares of the biotechnology company’s stock valued at $1,420,000 after buying an additional 17,483 shares during the last quarter. Geneos Wealth Management Inc. boosted its position in shares of Exelixis by 134.3% during the first quarter. Geneos Wealth Management Inc. now owns 1,647 shares of the biotechnology company’s stock valued at $61,000 after buying an additional 944 shares during the last quarter. Finally, Sivia Capital Partners LLC boosted its position in shares of Exelixis by 23.8% during the second quarter. Sivia Capital Partners LLC now owns 14,362 shares of the biotechnology company’s stock valued at $633,000 after buying an additional 2,764 shares during the last quarter. 85.27% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

EXEL has been the topic of several recent analyst reports. Citigroup cut Exelixis from a “market outperform” rating to an “underperform” rating in a research report on Monday, January 5th. Barclays increased their price objective on Exelixis from $44.00 to $45.00 and gave the company an “equal weight” rating in a research report on Monday, April 20th. Stifel Nicolaus increased their price objective on Exelixis from $43.00 to $44.00 and gave the company a “hold” rating in a research report on Wednesday, February 11th. Wall Street Zen cut Exelixis from a “strong-buy” rating to a “buy” rating in a research report on Saturday, April 18th. Finally, HC Wainwright raised their target price on Exelixis from $52.00 to $54.00 and gave the stock a “buy” rating in a research report on Thursday, February 12th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, eleven have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $47.00.

Exelixis Stock Performance

Shares of NASDAQ:EXEL opened at $43.68 on Friday. The stock has a market capitalization of $11.10 billion, a price-to-earnings ratio of 15.77, a PEG ratio of 0.98 and a beta of 0.38. The stock’s 50-day simple moving average is $43.31 and its two-hundred day simple moving average is $42.80. Exelixis, Inc. has a 52-week low of $33.76 and a 52-week high of $49.62.

Exelixis (NASDAQ:EXEL) last announced its earnings results on Tuesday, February 10th. The biotechnology company reported $0.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.20. Exelixis had a return on equity of 36.29% and a net margin of 33.73%.The business had revenue of $598.66 million for the quarter, compared to analysts’ expectations of $609.17 million. During the same period last year, the firm posted $0.55 earnings per share. The business’s revenue for the quarter was up 5.6% on a year-over-year basis. As a group, equities analysts forecast that Exelixis, Inc. will post 3.07 earnings per share for the current fiscal year.

Insider Activity at Exelixis

In related news, SVP Brenda Hefti sold 18,669 shares of Exelixis stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $44.01, for a total transaction of $821,622.69. Following the sale, the senior vice president owned 96,512 shares of the company’s stock, valued at approximately $4,247,493.12. This trade represents a 16.21% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Christopher J. Senner sold 30,617 shares of Exelixis stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $43.67, for a total value of $1,337,044.39. Following the sale, the chief financial officer directly owned 976,092 shares in the company, valued at $42,625,937.64. This trade represents a 3.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 362,849 shares of company stock worth $15,917,463 in the last three months. Corporate insiders own 2.82% of the company’s stock.

Exelixis Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.